Nanosystem functionalization strategies for prostate cancer treatment: a review.

Abstract

Prostate cancer (PC) has a high morbidity and mortality rate worldwide, and the current clinical guidelines can vary depending on the stage of the disease. Drug delivery nanosystems (DDNs) can improve biopharmaceutical properties of encapsulated anti-cancer drugs by modulating their release kinetics, improving physicochemical stability and reducing toxicity. DDN can also enhance the ability of specific targeting through surface modification by coupling ligands (antibodies, nucleic acids, peptides, aptamer, proteins), thus favouring the cell internalisation process by endocytosis. The purposes of this review are to describe the limitations in the treatment of PC, explore different functionalization such as polymeric, lipid and inorganic nanosystems aimed at the treatment of PC, and demonstrate the improvement of this modification for an active target, as alternative and promising candidates for new therapies.

• Authors: Jennifer Thayanne Cavalcante de Araújo, Jonatas Lobato Duarte, Leonardo Delello Di Filippo, Victor Hugo Sousa Araújo, Gabriela Corrêa Carvalho, Marlus Chorilli
• Journal: Journal of drug targeting (J Drug Target) Vol. 29 Issue 8 Pg. 808-821 (09 2021) ISSN: 1029-2330 [Electronic] England
• PMID: 33645369 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antineoplastic Agents

Topics

• Animals
• Antineoplastic Agents (pharmacology)
• Drug Delivery Systems (methods)
• Humans
• Male
• Nanoparticles (chemistry)
• Prostatic Neoplasms (drug therapy)